Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors

Apoptosis

Volumn 10, Issue 5, 2005, Pages 1143-1149

  Kondera Anasz, Z ^a   Mielczarek Palacz, A ^a   Sikora, J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

sFas; sFasL; Uterine tumors

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; STATISTICAL SIGNIFICANCE; UTERUS TUMOR;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; CYSTADENOCARCINOMA, SEROUS; FAS LIGAND PROTEIN; FEMALE; HUMANS; LEIOMYOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; SOLUBILITY; TUMOR NECROSIS FACTORS; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS;

EID: 24644482393     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-005-1018-9     Document Type: Article

References (32)

1. Furuya Y, Fuse H, Masai M. Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res 2001; 21: 3595-3598.
2. Lim SC. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncol Rep 2002; 9: 103-107.
3. Nagata S. Fas and Fas ligand: A death factor and its receptor. Adv Immunol 1994; 57: 129-144.
4. Kagi D, Vignaux F, Ledermann B, et al. Fas and perform pathway as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
5. Griffith TS, Ferguson TA. The role of FasL-mduced apoptosis in immune privilege. Immunol Today 1997; 18: 240-244.
6. Marsik C, Halama T, Cardona F, et al. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 2003; 20: 493-496.
7. Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol 1998; 160; 571-576.
8. Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999; 5: 3529-3533.
9. Nonomura N, Nishimura K, Ono Y, et al. Soluble Fas in serum from patients with renal cell carcinoma. Urology 2000; 55: 151-155.
10. Judo S, Kobayashi S, Nakajima Y, et al. Elevated serum levels of soluble Fas-APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998; 112: 166-171.
11. Konno R, Takano T, Sato S, Yajima A. Serum soluble Fas level as a prognostic factor in patents with gynecological malignancies. Clin Cancer Res 2000; 6: 3576-3580.
12. Hefler L, Mayerhofer K, Nardi A, et al. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000; 96: 65-69.
13. Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36.
14. Tsutsumi S, Kuwano H, Shimura T, et al. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000; 89: 2560-2564.
15. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870-3874.
16. Kato K, Ohshima K, Ishihara S, et al. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Hematol 1998; 103: 1164-1166.
17. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo. Hepatology 1999; 30: 413-421.
18. Sheets EE, Yeh J. The role of apoptosis in gynaecological malignancies. Ann Med 1997; 29: 121-126.
19. International Federation of Gynecologists and Obstetricians (FIGO). Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263-264.
20. Stellar H. Mechanism and genes of cellular suicide. Science 1995; 267: 1445-1449.
21. Lea GR, Riley SC, Antipatis C, et al. Cytokines and regulation of apoptosis in reproductive tissues: A review. Am J Reprod Immunol 1999; 42: 100-109.
22. Nagata S. Fas- induced apoptosis. Int Med 1998; 37: 179-181.
23. Strand S, Hofmann W, Hug H, et al. Lymphocyte apoptosis induced by CD94 (APO-1/Fas) ligand- expressing tumor cells a mechanism of immune evasion. Nature Med 1996; 2: 1361-1366.
24. Mor G, Straszewski S, Kamsteeg M. Role of the Fas/Fas ligand system in female reproductive organs: Survival and apoptosis. Biochem Pharmacol 2002, 64: 1305-1315.
25. Song J, Rutherford T, Naftolin F, Brown S, Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod 2002; 8: 447-455.
26. Das H, Koizumi T, Sugimoto T, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000; 82: 1682-1688.
27. Takagi A, Imai A, Horibe S, Ohno T, Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep 1998; 5: 377-380.
28. Maher S, Toomey D, Condron C, et al. Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80: 131-137.
29. Owen-Schaub LB, Angelo LS, Radinsky R, et al. Soluble Fas/APO-1 in tumor cells: A potential regulator of apoptosis? Cancer Lett 1995; 94: 1-8.
30. Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: Immune privilege and apoptosis. Mol Biotechnol 2003; 25: 19-30.
31. Micheau O, Solary E, Hammann A, et al. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-789.
32. Abrahams VM, Straszewski SL, Kamsteeg M, et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573-5581.